Faculty Information - Toshiko Ito-Ihara

（Last updated : 2026-05-12 16:30:27）

Toshiko Ito-Ihara
Department Kawasaki Medical School Kawasaki Medical School, Department of Translational and Clinical Innovation,

Position Professor

■ Present specialized field

Regulatory Science, Project Management, Nephrology (Key Word：Regulatory Science, Clinical Trial Management, Project Management in Clinical Research, Study Management, Drug and Medical Device Development)

■ Journal

1.	2026/03	Myeloperoxidase-anti-neutrophil cytoplasmic antibody positivity and disease characteristics, treatment, and prognosis in eosinophilic granulomatosis with polyangiitis.
2.	2026/03	Predictors of glucocorticoid-free clinical remission in patients with newly diagnosed microscopic polyangiitis and granulomatosis with polyangiitis: a retrospective cohort study using a nationwide registry in Japan (J-CANVAS).
3.	2026/03	Real-world effectiveness of rituximab or intravenous cyclophosphamide versus non-use in patients with severe microscopic polyangiitis and granulomatosis with polyangiitis: a retrospective cohort study of J-CANVAS.
4.	2026/02	Association Between Bronchiectasis and Serious Infections in Microscopic Polyangiitis and Granulomatosis With Polyangiitis From the J-CANVAS.
5.	2026/02	Effectiveness and safety of rituximab for remission maintenance therapy in microscopic polyangiitis and granulomatosis with polyangiitis in Japan: A retrospective multicenter cohort study (J-CANVAS).
6.	2026/01	Diabetes mellitus and cardiac disease as key predictors of rituximab-induced acute thrombocytopenia in ANCA-associated vasculitis.
7.	2025/12	Letter to the editor regarding Junker et al.: safety of computed tomography (CT)-guided percutaneous cryoablation in patients treated for clinical T1 renal cell carcinoma with the need for preprocedural ureteral stenting: an international cohort study.
8.	2025/11	Longitudinal MRI changes after focal therapy for prostate cancer: cryotherapy vs. microwave tissue coagulation.
9.	2025/11	Modification of 2022 ACR/EULAR ANCA-associated vasculitis classification criteria in a Japanese cohort (J-CANVAS).
10.	2025/11	Phenotype, serotype, and data-driven clustering reveal complementary dimensions of heterogeneity in ANCA-associated vasculitis: a multicentre Japanese cohort (J-CANVAS).
11.	2025/09	Clinical trial evaluating the efficacy and safety of percutaneous prostate cancer lesion-targeted microwave tissue coagulation for prostate functional preservation: MicroPro2.
12.	2025/09	Effectiveness for remission maintenance rate and safety of different rituximab regimens for treating anti-neutrophil cytoplasmic antibody-associated vasculitis in Japan: a J-CANVAS study.
13.	2025/07	Risk factors for cytomegalovirus reactivation during the treatment of ANCA-associated vasculitis: A retrospective cohort study of the J-CANVAS study.
14.	2025/06	Differences in phenotypes, treatments, and outcomes of ANCA-associated vasculitis across Europe, Japan and the USA in 2020.
15.	2025/06	Dr. Yoshida et al reply.
16.	2025/04	Glucocorticoid tapering pace in microscopic polyangiitis and granulomatosis with polyangiitis in Japanese real-world practice: A propensity score-matched retrospective cohort study from the J-CANVAS registry.
17.	2025/04	Temporal Evolution of multiparametric magnetic resonance imaging findings following lesion-targeted focal microwave tissue coagulation for localized prostate cancer.
18.	2024/12	Study protocol for LOMCAD Trial: Effect of lomerizine hydrochloride to prevent recurrence of cerebral ischemic events in CADASIL patients.
19.	2024/10	Effectiveness and safety of rituximab in severely relapsed antineutrophil cytoplasmic antibody-associated vasculitis: a retrospective analysis of a Japanese multicentre cohort from the J-CANVAS.
20.	2024/10	Exploratory trial of urethral submucosa injection therapy of deflux for stress urinary incontinence after radical prostatectomy.
21.	2024/09	Effectiveness of intravenous methylprednisolone pulse in patients with severe microscopic polyangiitis and granulomatosis with polyangiitis.
22.	2024/07	Optimal dose of intravenous cyclophosphamide during remission induction therapy in ANCA-associated vasculitis: A retrospective cohort study of J-CANVAS.
23.	2024/06	Seasonal Effects on Relapse of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Retrospective Multicenter Cohort Study in Japan (J-CANVAS).
24.	2024/05	Novel image-guided marker aimed at organ-preserving therapies for prostate cancer.
25.	2024/04	A Fully Automated Artificial Intelligence System to Assist Pathologists' Diagnosis to Predict Histologically High-grade Urothelial Carcinoma from Digitized Urine Cytology Slides Using Deep Learning.
26.	2023/12	Association between hypogammaglobulinaemia and severe infections during induction therapy in ANCA-associated vasculitis: from J-CANVAS study.
27.	2023/09	Seasonal Influence on Development of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Retrospective Cohort Study Conducted at Multiple Institutions in Japan (J-CANVAS).
28.	2023/07	Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial.
29.	2022/12	Microwave focal therapy of prostate cancer: a non-clinical study and exploratory clinical trial.
30.	2022/09	Plasma exchange and glucocorticoids to delay death or end-stage renal disease in anti-neutrophil cytoplasm antibody-associated vasculitis: PEXIVAS non-inferiority factorial RCT.
31.	2022/08	Hypertrophic pachymeningitis in ANCA-associated vasculitis: a cross-sectional and multi-institutional study in Japan (J-CANVAS).
32.	2022/02	The effects of plasma exchange in patients with ANCA-associated vasculitis: an updated systematic review and meta-analysis.
33.	2021/06	Recombinant human FGF-2 for the treatment of early-stage osteonecrosis of the femoral head: TRION, a single-arm, multicenter, Phase II trial.
34.	2021/04	Safety of Silk-elastin Sponges in Patients with Chronic Skin Ulcers: A Phase I/II, Single-center, Open-label, Single-arm Clinical Trial.
35.	2020/12	Impaired HVJ-stimulated Interferon producing capacity in MPO-ANCA-associated vasculitis with rapidly progressive glomerulonephritis lead to susceptibility to infection.
36.	2020/11	Recombinant human FGF-2 therapy for osteonecrosis of the femoral head: 5-year follow-up.
37.	2020/09	Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis.
38.	2020/05	Survey of Japanese dermatological vasculitis specialists on cases of cutaneous arteritis (cutaneous polyarteritis nodosa).
39.	2020/03	Establishment of optimal exercise therapy using near-infrared spectroscopy monitoring of tissue muscle oxygenation after therapeutic angiogenesis for patients with critical limb ischemia: A multicenter, randomized, controlled trial.
40.	2020/02	A Qualitative Study on the Differences Between Trial Populations and the Approved Therapeutic Indications of Antineoplastic Agents by 3 Regulatory Agencies From 2010 to 2018.
41.	2020/02	Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis.
42.	2016/08	A pilot study of regenerative therapy using controlled release of recombinant human fibroblast growth factor for patients with pre-collapse osteonecrosis of the femoral head.
43.	2016/05	Safety and efficacy of sustained release of basic fibroblast growth factor using gelatin hydrogel in patients with critical limb ischemia.
44.	2014/11	A randomized controlled clinical trial of topical insulin-like growth factor-1 therapy for sudden deafness refractory to systemic corticosteroid treatment.
45.	2013/10	An international survey of physicians regarding clinical trials: a comparison between Kyoto University Hospital and Seoul National University Hospital.
46.	2013/09	Clinical features of patients with anti-neutrophil cytoplasmic autoantibodies targeting native myeloperoxidase antigen.
47.	2010/06	Tumour necrosis factor alpha blockade impairs dendritic cell survival and function in rheumatoid arthritis.
48.	2008/12	Renal vasculitis in Japan and the UK--are there differences in epidemiology and clinical phenotype?
49.	2008	A comparative study of the diagnostic accuracy of ELISA systems for the detection of anti-neutrophil cytoplasm antibodies available in Japan and Europe.
50.	2007/03	Glomerulonephritis induced by methicillin-resistant Staphylococcus aureus infection that progressed during puerperal period.
51.	2007	Angiotensin II receptor blockade ameliorates mesangioproliferative glomerulonephritis in rats through suppression of CTGF and PAI-1, independently of the coagulation system.
52.	2007	Trafficking of QD-conjugated MPO-ANCA in murine systemic vasculitis and glomerulonephritis model mice.
53.	2006	Clinical efficacy of intravenous immunoglobulin for patients with MPO-ANCA-associated rapidly progressive glomerulonephritis.
54.	2004/10	Intravenous immunoglobulin (IVIg) therapy in MPO-ANCA related polyangiitis with rapidly progressive glomerulonephritis in Japan.
55.	2004/07	Neutrophil contribution to the crescentic glomerulonephritis in SCG/Kj mice.
56.	2000/05	Significantly high regional morbidity of MPO-ANCA-related angitis and/or nephritis with respiratory tract involvement after the 1995 great earthquake in Kobe (Japan).
Display 5 items
Display all(56)

■ Belonging society

1.	2011/01～	Japanese Society of Clinical Trials
2.	1993/07～	Japanese Society of Internal Medicine